Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors

被引：22

作者：

Cardinale, Jens ^{[1
]}

Roscher, Mareike ^{[1
]}

Schaefer, Martin ^{[1
]}

Geerlings, Max ^{[1
]}

Benesova, Martina ^{[1
]}

Bauder-Wuest, Ulrike ^{[1
]}

Remde, Yvonne ^{[1
]}

Eder, Matthias ^{[1
]}

Novakova, Zora ^{[2
]}

Motlova, Lucia ^{[2
]}

Barinka, Cyril ^{[2
]}

Giesel, Frederik L. ^{[3
]}

Kopka, Klaus ^{[4
]}

机构：

[1] German Canc Res Ctr, Div Radiopharmaceut Chem, D-69120 Heidelberg, Germany

[2] Czech Acad Sci, Lab Struct Biol, Inst Biotechnol, Vestec 25250, Czech Republic

[3] Univ Hosp Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany

[4] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut Canc Res, D-01328 Dresden, Germany

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 19期

关键词：

GLUTAMATE-CARBOXYPEPTIDASE-II; UREA-BASED INHIBITORS; PROSTATE-CANCER; PRECLINICAL EVALUATION; RADIATION-DOSIMETRY; DIAGNOSIS; LIGAND; PET/CT; F-18-PSMA-1007; BIODISTRIBUTION;

D O I：

10.1021/acs.jmedchem.9b01479

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer. In the present work, we report on the synthesis and preclinical evaluation of a series of F-18-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617. By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution. Selected compounds were co-crystallized with the PSMA protein and analyzed by X-rays with mixed results. Among these, PSMA-1007 (compound 5) showed the best interaction with the PSMA protein. The respective radiotracer [F-18]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clinical trials.

引用

页码：10897 / 10907

页数：11

共 50 条

[41] The development of an 18F-labeled luteinising hormone-releasing hormone receptor targeting peptide ligand series
Kertesz, I
Potari, N.
Joszai, I
Semjeni, M.
Rozsa, B.
Galuska, L.
Halmos, G.
ACTA PHYSIOLOGICA HUNGARICA, 2009, 96 (01) : 90 - 91
[42] Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging
Kelly, James
Amor-Coarasa, Alejandro
Nikolopoulou, Anastasia
Kim, Dohyun
Williams, Clarence, Jr.
Ponnala, Shashikanth
Babich, John W.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) : 647 - 661
[43] Dual-Tracer PET/CT in Non-Small Cell Lung Cancer: A Case Series Analysis Using [18F]FDG and [18F]F-PSMA-1007
Silveira, N.
Perroud-Junior, M.
Ide, H. Nakano
Amorim, B.
Lima, M.
Souza, C.
Lima, C.
Ramos, C. D.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S502 - S503
[44] Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging
James Kelly
Alejandro Amor-Coarasa
Anastasia Nikolopoulou
Dohyun Kim
Clarence Williams
Shashikanth Ponnala
John W. Babich
European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 647 - 661
[45] Performance of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients
Dietlein, Markus
Hohberg, Melanie
Kobe, Carsten
Dietlein, Felix
Zlatopolskiy, Boris
Krapf, Philipp
Neumaier, Bernd
Drzezga, Alexander
JOURNAL OF NUCLEAR MEDICINE, 2018, 59
[46] Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
Ahmadi Bidakhvidi, Niloefar
Laenen, Annouschka
Jentjens, Sander
Deroose, Christophe M.
Van Laere, Koen
De Wever, Liesbeth
Mai, Cindy
Berghen, Charlien
De Meerleer, Gert
Haustermans, Karin
Joniau, Steven
Everaerts, Wouter
Goffin, Karolien
EJNMMI RESEARCH, 2021, 11 (01)
[47] Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
Niloefar Ahmadi Bidakhvidi
Annouschka Laenen
Sander Jentjens
Christophe M. Deroose
Koen Van Laere
Liesbeth De Wever
Cindy Mai
Charlien Berghen
Gert De Meerleer
Karin Haustermans
Steven Joniau
Wouter Everaerts
Karolien Goffin
EJNMMI Research, 11
[48] Parameters Predicting [18F]PSMA-1007 scan Positivity and Type and Number of Detected Lesions in patients with Biochemical Recurrence of Prostate Cancer
Bidakhvidi, N. Ahmadi
Laenen, A.
Jentjens, S.
Deroose, C. M.
Van Laere, K.
Berghen, C.
Haustermans, K.
Joniau, S.
Everaerts, W.
Goffin, K.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S174 - S174
[49] High Affinity F-18 Labeled Prostate Specific Membrane Antigen (PSMA) Inhibitors: In Search of a Facile Approach to High Radiochemical Yield
Amor-Coarasa, A.
Kelly, J. M.
Ponnala, S.
Qu, W.
Babich, J. W.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S534 - S534
[50] Development of a novel PSMA targeted probe labeled witAl18F for prostate cancer imaging: Preclinicaland in-man evaluation
Liu, Teli
Liu, Chen
Zhu, Hua
Yang, Zhi
JOURNAL OF NUCLEAR MEDICINE, 2018, 59

← 1 2 3 4 5 →